In an open-access article published online on September 18, 2015 in Experimental & Molecular Medicine, scientists from Sungkyunkwan University School of Medicine in Seoul, Korea, show that levels of the serum exosomal microRNAs miR-18a, miR-221, miR-222, and miR-224 were significantly higher in patients with hepatocellular carcinoma (HCC) than in patients with either chronic hepatitis B (CHB) or liver cirrhosis (LC). Meanwhile, the scientists also showed that that the serum exosomal levels of miR-101, miR-106b, miR-122, and miR-195 were lower in those with HCC than in those with CHB. The scientists conclude that their data suggests that serum exosomal microRNA may be used as novel biomarkers for HCC. The EMM article is titled “Serum Exosomal MicroRNAs As Novel Biomarkers for Hepatocellular Carcinoma.”
[Experimental & Molecular Medicine article]
Login Or Register To Read Full Story